ChemoCentryx, Inc

Canaccord Genuity Acts as a Joint Bookrunner to ChemoCentryx Inc on its $301.6 Million Public Follow-On Offering

Canaccord Genuity is pleased to announce that on June 10, 2020, its client ChemoCentryx Inc (the “Company”) (Nasdaq: CCXI), completed an underwritten public follow-on offering for total gross proceeds to the Company of $301.6 million.

ChemoCentryx is a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. The Company is planning FDA and EMA submissions in 2020 for their lead drug, Avacopan, which targets ANCA-associated vasculitis.

Canaccord Genuity acted as a bookrunner to the Company. The Canaccord Genuity team included Eugene Rozelman, Jennifer Pardi, Brian O’Connor, Tara Hartigan, Mike Wright, Gaurav Mehta, Shawn Zamani, Tyler Chamberland, Esther Lee and Brooke Szczygiel.